Literature DB >> 26367783

High Frequency of Malignant Transformation of Ovarian Mature Teratoma into Squamous Cell Carcinoma in Young Patients in Northeast Brazil.

Iguaracyra B D O Araujo1, Marcos V C Pinheiro, Paulo H Zanvettor, Eduardo J B Studart, Deraldo F Filho, Sarah E Coupland.   

Abstract

The malignant behavior of an ovarian teratoma is related to immaturity, or rarely to the malignant transformation of a somatic component in a mature teratoma (MT). The aim of this work was to review 189 consecutive ovarian teratomas diagnosed between 2006 and 2010 at a public referral center for cancer in Brazil, focusing on cases of MT with malignant transformation. MTs with transformation to squamous cell carcinoma (SCC) were further analyzed by immunohistochemistry for p16 staining. The median age of all patients was 36 yr (mean age, 39.6 yr; SD±4.9). Mature and immature teratomas represented 95.7% (181/189) and 4.2% of the cohort, respectively. Immature teratoma occurred mainly in adolescents under 18 yr. Malignant transformation of the somatic component in MT was observed in 10 of 181 patients (5.5%). SCC was the most common subtype (4/10), followed by differentiated thyroid carcinoma in struma ovarii(3/10), adenosquamous carcinoma (1/10), mucinous intestinal-type adenocarcinoma (1/10), and a well-differentiated neuroendocrine tumor/carcinoid (1/10). Two of 4 SCC cases were strong and diffusely positive for p16, and 2 were negative. In 5 further patients, MT was synchronously observed with other benign and malignant ovarian neoplasms in the ipsilateral ovary (3 mucinous cystadenomas and 1 Brenner tumor) and 1 cystadenocarcinoma in the contralateral ovary. MTs with malignant transformation were larger than those without transformation (P<0.001), but did not demonstrate any association with age. Indeed, our patients with SCC in MT were much younger [median and mean age, 37 and 38 yr (SD±4.9), respectively] than those described previously. As p16 is considered a surrogate marker for HPV infection, the malignant transformation of MT into SSC in young patients raises the possibility of HPV infection as a risk factor in some of these cases. However, molecular studies are needed to clarify the possible role of HPV in the malignant transformation of MT to SCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26367783     DOI: 10.1097/PGP.0000000000000225

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  30-Year Experience With 22 Cases of Malignant Transformation Arising From Ovarian Mature Cystic Teratoma: A Rare Disease.

Authors:  Yan Li; Meng Qin; Ying Shan; Huan-Wen Wu; Xiao-Ding Liu; Jie Yin; Yu Gu; Wei Wang; Yong-Xue Wang; Jia-Yu Chen; Li Ma; Ying Jin; Ling-Ya Pan
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

2.  Malignant Transformation of Mature Cystic Teratoma Diagnosed after a 10-Year Interval.

Authors:  Mariko Jitsumori; Satoru Munakata; Toshiya Yamamoto
Journal:  Case Rep Obstet Gynecol       Date:  2017-05-21

3.  A Squamous Cell Carcinoma and a Malignant Fibrous Histiocytoma Developing in a Patient with a Mature Cystic Teratoma.

Authors:  Ali Emre Tahaoglu; Serhat Ege; Mehmet Sait Bakir; Gülbin Saruhan; Serif Aksin; Talip Gul
Journal:  Case Rep Oncol       Date:  2017-01-19

4.  Malignant transformation in mature cystic teratoma of the ovary: a retrospective study of eight cases and review of literature.

Authors:  Ruchi Rathore; Sonal Sharma; Sarla Agarwal
Journal:  Prz Menopauzalny       Date:  2018-06-30

5.  Malignant transformation arising from mature ovarian cystic teratoma: A case series.

Authors:  Li Qin; Tao Zhao; Xin Liu; Hongli Wang; Xin Gu; Dian Chen; Zaiping Wang; Du He
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

Review 6.  Rare case of squamous cell carcinoma arising in a recurrent ovarian mature cystic teratoma of a young woman: A case report and review of the literature.

Authors:  Xinge Feng; Lian Xu
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.